medical marijuana Archives - Green Market Report

StaffStaffMay 13, 2020
shutterstock_660308902-1280x796.jpg

9min12080

Ever since recreational cannabis has stolen the stage, people tend to forget that cannabis is one of the oldest and most trusted medicines on the planet.

The medicinal properties within the plant are responsible for managing the symptoms associated in patients suffering from Epilepsy, Autism, Crohn’s Disease, Cancer, PTSD, and Chronic Pain to name just a few.

These brands have developed some of the best practices and formulations in the industry to treat a myriad of ailments with patents pending across the globe.

Our team decided to break down a list of the most respected medical brands and products within the cannabis industry globally.

Here they are:

 

1.) Charlotte’s Web:

More than just CBD: CBD plus naturally-occurring phytocannabinoids, terpenes, flavonoids and more in every CBD oil serving. The team from Charlotte’s Web uses limited, select ingredients to ensure you have the absolute best hemp extract possible. Their CBD oils include Charlotte’s Web premium hemp extract, carrier oil, and flavor. That’s it. Their products are U.S. Hemp Authority Certified. Charlotte’s Web CBD oils are whole-plant extracts that include a variety of of beneficial compounds, including phytocannabinoids, terpenes, flavonoids, and essential fatty acids.

 

2.) Aunt Zelda’s:

Aunt Zelda’s is a pioneering, data-driven developer of cannabis-based plant medicines. Our products are the result of years of research and development by founders, Mara Gordon and Stewart Smith, in consultation with knowledgeable physicians and world-renowned researchers.

Utilizing proven time-tested extraction processes improved with modern technology, Aunt Zelda’s offers medicines of precisely measured potency and purity that empower patients to dose to the milligram and unlock the therapeutic potential of cannabis.

If you prefer to obtain lab tested products created for specific ailments, Aunt Zelda’s will help you get there!

Aunt Zelda’s mission is to alleviate patient suffering through medical cannabis.  We help you, our patients, live fulfilling, healthy lives.

They provide unmatched expertise in the correct use of medical cannabis matched to disease-specific products with the highest purity in California.

Their goal is to create a positive and supportive community for medical cannabis users. They aspire to be your trusted source of cannabis resources and its safe, effective and responsible use

 

3.) HOPE Grows for Autism:

Formulation by: Zelira Therapeutics

HOPE is a Proprietary formulation specifically to address patient symptoms associated with Autism Spectrum Disorder.  The HOPE® Franchise has received support from organizations such as HOPE Grows for Autism, a leading autism advocacy group based in Pennsylvania. It has been the top performing product within the state and will soon be available for patients in Louisiana and throughout the US and Australia. 

In a company press release in December 2019, Zelira Therapeutics leadership said, “Our company will have the ability to distribute the HOPE® portfolio along with our additional products through licensing agreements with multi-state and international operators…”

HOPE 1 and HOPE 2 are part of a growing family of proprietary medical marijuana formulations. HOPE™ is created by extracting, isolating, and then re-assembling the medicinal compounds from the marijuana plant to achieve specific, targeted effects. HOPE™ was formulated with autism in mind and has quickly proved to be beneficial to other chronic conditions such as chronic pain, anxiety, neuropathy and others. HOPE™ has since become its manufacturer’s best-selling tincture.

 WHAT FORMS OF HOPE ARE AVAILABLE?

Available as a tincture, blended in 100% olive oil.

WHAT MAKES UP HOPE?

THC + CBD + Terpenes

Found in the trichomes of the plant, terpenes are plant oils with unique aromas and distinctive​ flavors (pine, citrus, mint) and are known to play​ a key role on the overall effects of each strain. ​ Terpenes also play a key role in differentiating​ the flavor and scent of marijuana. Some terpenes​ might promote relaxation, while others energy or​ focus.

 

4.) Ilera Holistic Healthcare:

ALAFIA — which means ‘inner peace’ in the Nigerian “Yoruba” language — is scientifically formulated, lab tested and pesticide free. Currently on the market are two formulated PURE CBD tinctures: Isolate CBD with 500mg and 1000mg  and Full Spectrum CBD with 500mg and 1000mg.  This product is Additional CBD products will be released at dispensaries in the state of Louisiana only.

“Our vision has always been patient access and affordability,” said Chanda Macias, chief executive officer of Ilera Holistic Healthcare. “It was imperative for us to bring high-quality products that support health and wellness.  Patients now have the ability to purchase ALAFIA over the counter without a prescription anywhere it is available.”  Dr. Chanda Macias said back in January 2020

5.) Haleigh’s Hope:

Extra strength has double the concentration than the regular strength, allowing the consumer to take less oil but still get the same desired therapeutic effect as the regular strength. Extra Strength products are recommended for people over 100 lbs.

This organically grown, whole plant extract contains a broad spectrum of naturally occurring plant based compounds that are clinically proven to provide a powerful combination of antioxidants and neuroprotectants. Haleigh’s Hope® was created from a proprietary genetic plant strain that was carefully bred and cultivated over seven years to achieve a precise combination of clinically proven, therapeutic plant compounds..

Haleigh’s Hope® grows, extracts, produces, packages and ships 100% of our product from our facilities in Colorado. Because we have exclusive control over our products from seed to sale, we ensure the highest levels of quality and consistency in the industry. Every batch of our product is lab tested for safety and quality.

Safflower is a cold pressed seed oil that is non-GMO and organic, and does not need to be shaken.

Exclusively grown and manufactured in Colorado, USA.


StaffStaffApril 29, 2020
Hemp-Growing-small_1.jpg

4min5492

Medical Marijuana, Inc. (OTC: MJNA) reported financial results for the quarter and year ending Dec. 31, 2019, with $75.6 million in gross revenue in 2019, a 26.3% increase year-over-year when compared to 2018’s gross revenue of $59.8 million. The net ordinary income for 2019 was $3.3 million versus 2018’s net loss of $8 million. The company reported a positive adjusted EBITDA of $139 thousand in 2019 as compared to a loss of $1.2 million in 2018. 

The GAAP net income for the fourth quarter increased to $84,404 versus 2018’s net loss of $202,630.

“In 2019, Medical Marijuana, Inc. and its subsidiaries continued to execute on our strategic growth and fiscal responsibility action plan that rendered our best results yet and I could not be more excited to share them with shareholders,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We were able to not only generate increased revenues but focus on our bottom line by making strategic adjustments to expenditures.”

“In addition to our success in the U.S., our international operations have continued to flourish in EuropeLatin America and we are excited for our development in Asia,” said Medical Marijuana, Inc. COO Blake Schroeder. “We hope that these efforts will continue to build shareholder value and help bring our industry-leading products to broader audiences worldwide.”

In 2019, Medical Marijuana, Inc. listed the following highlights:

  • The Company was recognized as a top-five hemp-derived CBD company by Yahoo Finance
  • Subsidiaries HempMeds® and Kannaway® became the first companies to have their CBD products listed in the Prescribers’ Digital Reference
  • Subsidiaries HempMeds®, Dixie Botanicals® and Kannaway® received the U.S. Hemp Authority Certification Seal
  • Dr. Titus was invited to speak at the FDA Hearing on Cannabis and CBD Products in May 2019
  • Brooke Beers was promoted to Chief Financial Officer

StaffStaffMarch 17, 2020
shutterstock_1189081114-1280x989.jpg

7min25060

Editors Note: This is a guest post by Tiffani Wroe

Though the numbers increase every year, not all states have legalized recreational marijuana — most merely permit the medicinal use of marijuana to treat various physical and mental ailments. Yet, even in states where recreational weed is legal, plenty of residents pursue medical marijuana permits, despite the fact that they can obtain recreational weed without the hassle of doctors’ appointments and prescriptions. 

There are noteworthy differences in medical marijuana and recreational marijuana — both in how the drug is sold and what varieties of the drug are available. If you live in a state where recreational marijuana has been legalized, you might still consider seeking a medical marijuana card. Here’s why.

How Medical Marijuana and Recreational Marijuana Differ

Currently, marijuana remains a Schedule I drug at the federal level, and states are responsible for regulating both medicinal and recreational cannabis. Thus, the differences between medical marijuana and recreational marijuana will vary from place to place; some states have tight restrictions on who can obtain medical weed and how medical weed can be sold while other states have an exceedingly blurry line between the cannabis products everyone can acquire and those reserved for the medically ailing. it is important that you research and understand the marijuana laws in your area, so you can make fully informed decisions about your weed use. 

Medical marijuana is intended for use treating diseases that are otherwise difficult to manage with other medications and therapies. Every state where medicinal weed is legal has a list of illnesses for which marijuana can be legally prescribed; they often contain baffling conditions like chronic pain and nausea, muscle spasms, Crohn’s disease, Parkinson’s disease, post-traumatic stress disorder, multiple sclerosis, and glaucoma —but again, you should investigate the qualifying diseases in your state. 

Regardless of what medicinal weed is used to treat, it needs to have an effect on its users. Thus, medical marijuana tends to have much higher THC and CBD content to ensure that the drug is having an impact. Additionally, medical marijuana endures much more rigorous testing to ensure purity and potency. Sufferers of the worst diseases need to be able to trust that their treatment will help and not hurt, so medical-grade marijuana tends to be more tightly controlled.

Recreational marijuana is intended only for recreational use — which is to say that it should be taken for fun and enjoyment, not any kind of treatment. While many states still regulate recreational weed to some degree, the testing is not nearly as meticulous as it is for medicinal marijuana. As a result, there tends to be much more variety of weed strains and products in recreational dispensaries, with a great diversity of THC and CBD levels. Often, recreational users cannot obtain the sky-high THC content strains as are available to medical users. 

How Medical and Recreational Dispensaries Differ

 It isn’t just weed products that differ — it is the dispensaries themselves. Though some states do allow for dispensaries to hold both recreational and medicinal sales licenses, most dispensaries are one or the other. As a result, medical marijuana users need to be careful to look for the right dispensaries, just as I always search specifically for a recreational dispensary near me.

You can think of medical marijuana dispensaries like pharmacies — because that is essentially what they are. The budtenders behind the counters at medical dispensaries are more highly trained to assist with delivering the right marijuana product to different kinds of marijuana patients. They are permitted to ask about conditions and symptoms, and they are allowed to maintain health records to better meet your medicinal needs in the future. However, to gain access to this high-quality service, you will need a recommendation from a healthcare professional or a medical marijuana license from your state.

Meanwhile, recreational dispensaries are much less intensive. While you will need to provide evidence of your age — all states currently require recreational users to be 21 years or over — you will have much more freedom to choose weed products that interest you. You can ask budtenders at recreational dispensaries some questions about strain potency and effects, but in many places, they cannot legally answer questions related to medical use. Thus, if you have pain or anxiety you would like to mitigate with marijuana, you might be better off obtaining your medical card.

For many, marijuana is a miracle drug that pleasantly alleviates some of the worst symptoms of disease. However, even in states where recreational weed is legal, some users need to obtain medical permission to obtain the right products to treat their conditions. Instead of managing with what is available at your recreational dispensary, you might benefit greatly from strains reserved for medicinal use — which means you might just need a medical marijuana card in 2020. 

 


StaffStaffFebruary 10, 2020
Illinois-scaled.jpg

5min7461
Editors Note: This is a guest post from Teresa Martin.
Complaints from patients across the state prompted an advisory from the Illinois Department of Financial Professional Regulation for dispensary operations across the state on Friday. The complaint was directed at possible shortages of patients’ normal medical purchases, due to recreational sales.
New mandates from regulators state that a dispensary must leave a window open solely for medical sales. Dispensaries must not hold products back for recreational sales. Medical patients must be able to purchase 2.5 times the amount set by a dispensary, for any recreational sales. Cannabis supply for medical patients has eased somewhat, since the first of the year, in the Champaign – Urbana area of Illinois, as of this writing on February 7, 2020.
Access to medicinal cannabis has taken some ups and downs for the last couple of months. Patients are still being treated to first of the line service in the area as dispensaries try to keep up with the demand from recreational marijuana sales that started January 1, 2020.
The first day of recreational sales in the Twin Cities was robust and lines were wrapped around buildings. For hours, potential customers stood in inclement weather to be part of history. Most were happy to just wait patiently for their turn at purchasing marijuana, which has been illegal in this state, except for people with certain conditions, until now.
Medical patients were directed to the front of the line in order to have access to plenty of medicinal choices.
Cresco Labs, which is the operator of Sunnyside dispensary in  Champaign Il has been able to offer its medical patients a limited, though steady amount of offerings since the first of the year. NU Med dispensary in Urbana, Il has had similar effects on the demand for cannabis being played out.
The supply for both medical cannabis and recreational has varied in the one plus months since the beginning of recreational sales. Some days, sales are only open to medical patients to keep a supply for their demand intact.
The following shows the supply for medical cannabis for the current day of February 7, 2020. These two cannabis dispensaries are the only two currently operating in this east central Illinois area.
Sunnyside Dispensaries listed on their medical menu the following:
• Flower 19
• Concentrates  8
• Edibles  90
• Topical 14
• Vapes 89
• Tincture 5
Unique items included tonics, cereal, teas, and bath salts
NuMed dispensary offerings were:
• Flower 2
• Concentrates
• Edibles 78
• Topical 12
• Vapes 72
• Tincture 2
• Tablet & Capsules 14
Some of their unique offerings include oatmeal, teas, body oil, and suppositories.
It is yet to be seen if these new regulations will help to ease the cannabis demand, for medical patients. Putting your states medical patients first is a step in the right direction for helping to alleviate the pain of some 100,000 patients in the state.

William SumnerWilliam SumnerJuly 30, 2019
new-york-31503_6401.png

4min25880

On July 29, 2019, New York Gov. Andrew Cuomo signed into law a measure that reduces the penalties for cannabis possession.

“While the failure to pass a comprehensive legalization bill is an unfortunate loss to the taxpayers of New York, the decriminalization of small amounts of cannabis is significant progress for social justice initiatives, an underreported aspect of the legalization movement,” said Evan Eneman, CEO of MGO|ELLO Alliance, a cannabis finance and banking firm.

Although New York decriminalized the possession of 23 grams or less of cannabis in 1977, tens of thousands of New Yorkers have still found themselves arrested and charged with possessing small amounts of cannabis. Between 2008 and 2017, approximately 360,000 people have been arrested for cannabis possession, the majority of which have been persons of color.

“Communities of color have been disproportionately impacted by laws governing marijuana for far too long, and today we are ending this injustice once and for all,” Cuomo said in a statement. “By providing individuals who have suffered the consequences of an unfair marijuana conviction with a path to have their records expunged and by reducing draconian penalties, we are taking a critical step forward in addressing a broken and discriminatory criminal justice process.”

Though the majority of New York residents support cannabis legalization, the state legislature failed this year to pass a full-legalization bill. The primary reason for the bill’s failure was to due to disagreements over diversity requirements for licensees. To many, the recently passed decriminalization bill is seen as a stop-gap measure while the legislature works out the details of full legalization.

The new law reduces cannabis possession to a violation punishable by a fine and removes criminal penalties for cannabis possession under two ounces. The measure also creates a process for individuals charged with cannabis possession to have their records expunged, both retroactively and for future convictions.

Individuals caught possessing cannabis will be fined $50 for the first offense and fined $200 for a second offense within three years of the first violation. Those caught for a third time within three years will be subject to a $250 fine and/or 15 days in jail. The new law will go into effect on August 29, 2019.

Medical Marijuana Inc.’s (OTC: MJNA) Dr. Stuart Titus said, “New York has a history of leading the way in many legislative policies for the U.S. and we hope that this new decriminalization measure in New York will set an example for other states, and the federal government to follow.”

The illegal nature of cannabis hasn’t frightened the investors away. Eneman added, “The cannabis industry isn’t waiting for regulators to catch up, as demonstrated by the record-setting pace of venture capital investing, as detailed in the MGO | ELLO Cannabis Private Investment Review. The report shows investment exceeding $1.3 billion already through the first half of this year as compared to $1B in total in 2018. Investors have a strong appetite for cannabis and they aren’t letting roadblocks like legalization stand in their way.”


Video StaffVideo StaffSeptember 20, 2018

1min8350

The Green Market Summit hosted by the Green Market Report on September 14, 2018, featured a panel that looked into the effect of a legalized adult use marijuana market on existing medical marijuana markets. Panelists included Adam Orens of Marijuana Policy Group, Jeannette Horton and Jessica Billingsley from MJ Freeway and Emily Paxhia of Poseidon Asset Management.

The panel resulted in a new report issued at the Summit titled, “The Economics of Adult Use Marijuana on Medical Marijuana Markets.” The findings from the data provided by MJ Freeway noted that instead of adult use legalization cannibalizing medical marijuana markets, the medical markets turn out to be very resilient.


Video StaffVideo StaffAugust 13, 2018

3min14900

iAnthus Capital Holdings (ITHUF) recently broke ground for its new medical marijuana facility in Warwick, New York. The company and its subsidiary, Citiva are celebrating the groundbreaking of its medical cannabis facility.

Citiva is one of only ten licensed medical cannabis producers in New York State. This location used to be the Mid-Orange Correctional Facility, and will eventually support up to 125,000 square feet of total cultivation and processing space, with an estimated yearly medical cannabis production of 2,400 kg.

“We’re excited to be taking the first steps in building out our robust and comprehensive medical cannabis program in the State of New York. The iAnthus and Citiva teams have worked incredibly hard to reach this milestone,” said Hadley Ford, CEO of iAnthus Capital. “The growth and success of our Warwick facility will lay the foundation for the rest of our operations across New York State, and we look forward to continued expansion, development, and most importantly, service to our patients, through our vertically integrated operations.”

According to the company statement, Phase 1 of the buildout is projected to be completed in the first half of 2019. The Warwick site can eventually support up to 125,000 sq. ft. of total cultivation and processing space and will be built out in several phases. Citiva purchased the eight and a half acres of land for the Warwick facility in May of 2018 for US$526,000.

Warwick is pleased to welcome one of the nation’s leaders in the medical marijuana industry to the Warwick Technology Park and is honored that Citiva has found a home in our town,” said Michael SweetonTown of Warwick Supervisor. “Our goal in acquiring the Mid-Orange Correctional Facility was to bring well-paying jobs to the area, and we look forward to seeing this come to fruition through the official groundbreaking of Citiva’s medical cannabis facility.”


Debra BorchardtDebra BorchardtJune 25, 2018
epidiolex-medical-marijuana-1280x800-1280x800.jpg

8min29101

The U.S. Food and Drug Administration (FDA) approved GW Pharmaceuticals’ (GWPH) cannabidiol (CBD) drug Epidiolex as an oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome, and Dravet syndrome, in patients two years of age and older. According to the press release, this is the first FDA-approved drug that contains a purified drug substance derived from marijuana and it is also the first FDA approval of a drug for the treatment of patients with the Dravet syndrome.

“Today, the FDA approved a purified form of the drug cannabidiol (CBD). This is one of more than 80 active chemicals in marijuana. The new product was approved to treat seizures associated with two rare, severe forms of epilepsy in patients two years of age and older,” said FDA Commission Scott Gottlieb, M.D.

He went on to add, “But it’s also important to note that this is not an approval of marijuana or all of its components. This is the approval of one specific CBD medication for a specific use. And it was based on well-controlled clinical trials evaluating the use of this compound in the treatment of a specific condition. Moreover, this is a purified form of CBD. It’s being delivered to patients in a reliable dosage form and through a reproducible route of delivery to ensure that patients derive the anticipated benefits. This is how sound medical science is advanced.”

Gottlieb cautioned though that he remains concerned about the proliferation and illegal marketing of unapproved CBD-containing products with unproven medical claims. The FDA has taken action against companies making unsupported CBD claims in the past couple of years and the agency said it would continue to do so.

GW Says Rescheduling Within 90 Days

Even though the FDA has now approved the use of Epidiolex as a real treatment for these diseases, it doesn’t immediately change the status of cannabis as a controlled substance. The two defining factors of the schedule one designation include not having a medicinal purpose and being a highly addictive drug.

The FDA release stated, “Under the Controlled Substances Act (CSA), CBD is currently a Schedule I substance because it is a chemical component of the cannabis plant. In support of this application, the company conducted nonclinical and clinical studies to assess the abuse potential of CBD. The FDA prepares and transmits, through the U.S. Department of Health and Human Services, a medical and scientific analysis of substances subject to scheduling, like CBD, and provides recommendations to the Drug Enforcement Administration (DEA) regarding controls under the CSA. DEA is required to make a scheduling determination.”

The FDA did not say in its release whether it had delivered a recommendation to the DEA regarding Epidiolex and its schedule status.

However, in GW Pharmaceutical’s statement, the company said it would have to be rescheduled before it could be made available to patients. “Rescheduling is expected to occur within 90 days. Access is expected to be similar to other branded AEDs and EPIDIOLEX is expected to be available to appropriate patients by Fall 2018.”

“While we applaud the FDA for confirming what many of us have long known–that the benefits of cannabis are immense–we do find it a bit comical that the federal government now contradicts itself once again,” said Chris Driessen, President of Organa Brands U.S. “While the FDA touts the benefits of this new drug, the DEA maintains a Schedule One classification for cannabis, stating that it has no medical application and a high potential for abuse. We have to ask–does the left hand know what the right hand is doing?

Management Comments

“Today’s approval of EPIDIOLEX is a historic milestone, offering patients and their families the first and only FDA-approved CBD medicine to treat two severe, childhood-onset epilepsies,” said Justin Gover, GW’s Chief Executive Officer. “This approval is the culmination of GW’s many years of partnership with patients, their families, and physicians in the epilepsy community to develop a much needed, novel medicine. These patients deserve and will soon have access to a cannabinoid medicine that has been thoroughly studied in clinical trials, manufactured to assure quality and consistency, and available by prescription under a physician’s care.”

“In my practice, I often see patients with these highly treatment-resistant epilepsies who have tried and failed existing therapies and are asking about CBD,” said Orrin Devinsky, M.D., of NYU Langone Health’s Comprehensive Epilepsy Center and a lead investigator in the EPIDIOLEX clinical program. “I am delighted that my physician colleagues and I will now have the option of a prescription cannabidiol that has undergone the rigor of controlled trials and been approved by the FDA to treat both children and adults.”

“For those living with intractable seizures caused by LGS and Dravet syndrome, EPIDIOLEX represents a true medical advancement,” said Philip Gattone, president and CEO of the Epilepsy Foundation.  “Clinical development for these rare and severe conditions is essential, and today’s news brings hope for these patients and their families that a new treatment option may have the potential to help better control their seizures.”

Epidiolex

Epidiolex’s effectiveness was studied in three randomized, double-blind, placebo-controlled clinical trials involving 516 patients with either Lennox-Gastaut syndrome or Dravet syndrome. Epidiolex, taken along with other medications, was shown to be effective in reducing the frequency of seizures when compared with placebo. It uses CBD, which is a chemical component of the Cannabis sativa plant. CBD does not give patients a psychotropic effect like getting “high” that comes from the other part of the cannabis plant –  tetrahydrocannabinol (THC).

 


Debra BorchardtDebra BorchardtJune 5, 2018
doctor.jpg

4min42800

A new report from Arcview Market Research and BDS Analytics says that the medical marijuana market will drop to only 41% in 2018 as the California, Nevada and Canada adult-use markets explode. Medical marijuana accounted for 71% of the legal market in 2017, making the pace of the decline dramatic. The State of Legal Marijuana Markets 6th Edition also predicts that the medical component of worldwide legal sales will plunge to just 35% by 2022 due to the growth of recreational sales in those three markets, along with new states like Maine and Massachusetts.

Consumer spending in cannabis markets is expected to triple to $32 billion by 2022 for a 27.5 compound annual growth rate (CAGR). The report notes that U.S. sales alone will grow to $23.4 billion by 2022. It seems Americans are the most excited about adult use marijuana as the paper says that it is largely a U.S. phenomenon.  The rest of the world appears to be content to stick with just medical marijuana.

Uruguay and Switzerland allow for sales of recreational cannabis, but the Swiss limit it to pre-rolls with up to 1% THC. Germany recently opened to medical sales in 2017, which was a big leap for Europe but won’t move the needle in global sales.

Another area that the report highlights as changing is the decline in flower’s total sales in relation to the market. The report says that vape sales have grown 86% from 2016 to 2017 followed by live resin which has grown 80%. Oils have grown by 40% “California’s extract market, where the vape subsector comprises 71% of all concentrate sales makes high-quality vapes a hot opportunity for companies looking to enter the market.”

Investing in cannabis has changed too. “Despite a pullback since 2018 began, the top four Canadian LP’s were valued at a total of C$10 billion at the end of April, about twice our 2022 forecast for consumer spending in the entire Canadian market.” The report also pointed out the softening stance by the stock exchanges in the U.S. Initially the exchanges wouldn’t allow any plant touching companies to list, but now Cronos Group (CRON) from Canada is on the NASDAQ and Canopy Growth (CGC) is on the New York Stock Exchange.

The cannabis friendly Canadian Securities Exchange lists about $5 billion in cannabis-related companies out of a total of C$9 billion in market cap for 354 companies. 23 of those companies are U.S. based. The report also noted that while some investors continue to avoid plant touching companies to stick with ancillary investments, Constellation Brands (STZ) jumped in with its 10% stake in Canopy Growth.

Looking Ahead

The report says that despite movements from other countries like Germany, North America will continue to lead the way in legal cannabis spending. South America is also building its programs as Uruguay takes big steps forward as the first federally legal adult-use market. While many believe legalization will only mean an upside to the industry, the report cautions that strict regulations keep the black market intact. It also predicts that prices will fall and that the availability in attractive retail environments will expand.



About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 4 hours

Clever Leaves To List On NASDAQ $SAMA $NDAQ ⁦@clever_leaves⁩

@GreenMarketRpt – 7 hours

Leafs By Snoop Is Most Recognizable Brand Says New Study $CGC ⁦@SnoopDogg⁩ ⁦@MERRYJANE⁩ #LBS…

Back to Top

You have Successfully Subscribed!